NEJM:CTA检查不能改善冠脉疾病(CAD)治疗效果

2015-04-03 MedSci译 MedSci原创

背景:很多病人发生冠心病(CAD)之前会出现先兆症状,尽管通过随机试验得出诊断的数据很少,但大家普遍通过使用诊断性操作判断评估患者病情。方式:我们随机选取10003位出现冠心病先兆症状的患者接受冠状动脉CT血管造影(CTA)(我们称之为实验组)或功能性测试(使用运动心电图、核压力测试、负荷超声心动图)(我们称之为对照组)进行试验。我们关注的主要指标是患者死亡率、心肌梗塞和因不稳定性心绞痛住院、出现

背景:
很多病人发生冠脉疾病(CAD)之前会出现先兆症状,尽管通过随机试验得出诊断的数据很少,但大家普遍通过使用诊断性操作判断评估患者病情。


方式:
我们随机选取10003位出现冠心病先兆症状的患者接受冠状动脉CT血管造影(CTA)(我们称之为实验组)或功能性测试(使用运动心电图、核压力测试、负荷超声心动图)(我们称之为对照组)进行试验。我们关注的主要指标是患者死亡率、心肌梗塞和因不稳定性心绞痛住院、出现主要并发症的患者人数;我们关注的次要指标是导管介入术后不显示梗阻性冠心病的患者人数和辐射暴露剂量。

结果:
参与实验的患者平均年龄为60.8岁(年龄范围在52.5-69.1岁),女性占52.7%,有87.7%的患者有胸痛或吸气性呼吸困难。预实验表明有梗阻性心梗可能性的患者占53.3%(范围在31.9%-74.7%)。在为期25个月的跟踪随访中,我们发现,在接受CTA检查组即实验组中,4996名患者中有164名患者出现了我们关注的主要指标,占3.3%;在接受功能性测试患者组即对照组中,5007名患者中有151名患者出现率我们关注的主要指标,占3.0%,调整后危险比为1.04,95%可信区间为0.83到1.29,P=0.75。相比对照组而言,尽管实验组患者90天内接受介入术的病人数目更多(为12.2%:8.1%),但导管介入术后显示无阻塞性CAD的患者数更少(为3.4%:4.3%,P=0.02),就介入术后平均每位患者辐射暴露量而言,实验组低于对照组(10.0mSv: 11.3mSv),但是对照组有32.6%的患者没有辐射暴露,所以,就总暴露量而言,实验组高于对照组(12.0 mSv vs. 10.1 mSv; P<0.001)。

结论:
2年的随访调查表明,对于怀疑CAD并已出现先兆症状且接受非侵入性操作的患者而言,相比功能性测试而言,CTA检查并不能改善治疗效果。

原文出处:
Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, Cole J, Dolor RJ, Fordyce CB, Huang M, Khan MA, Kosinski AS, Krucoff MW, Malhotra V, Picard MH, Udelson JE, Velazquez EJ, Yow E, Cooper LS, Lee KL; PROMISE Investigators.Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. N Engl J Med. 2015 Apr 2;372(14):1291-1300. Epub 2015 Mar 14.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=60803, encodeId=b3ec60803a2, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60804, encodeId=3a9b608049d, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60805, encodeId=d31360805de, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60807, encodeId=04036080e8e, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893885, encodeId=7f0e18938852a, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 06 08:26:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849508, encodeId=f3cd184950893, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed May 27 22:26:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19551, encodeId=022719551ca, content=预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9daf1619121, createdName=Keren1970, createdTime=Sun Apr 05 20:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572975, encodeId=949415e29759a, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sun Apr 05 11:26:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19485, encodeId=b846194853a, content=外国人工作就是细致, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Sun Apr 05 07:50:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19474, encodeId=6b0f194e442, content=感觉挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Apr 05 01:09:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2016-01-27 doctording1

    不错,赞一个

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=60803, encodeId=b3ec60803a2, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60804, encodeId=3a9b608049d, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60805, encodeId=d31360805de, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60807, encodeId=04036080e8e, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893885, encodeId=7f0e18938852a, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 06 08:26:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849508, encodeId=f3cd184950893, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed May 27 22:26:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19551, encodeId=022719551ca, content=预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9daf1619121, createdName=Keren1970, createdTime=Sun Apr 05 20:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572975, encodeId=949415e29759a, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sun Apr 05 11:26:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19485, encodeId=b846194853a, content=外国人工作就是细致, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Sun Apr 05 07:50:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19474, encodeId=6b0f194e442, content=感觉挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Apr 05 01:09:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2016-01-27 doctording1

    这篇文章有一定深度

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=60803, encodeId=b3ec60803a2, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60804, encodeId=3a9b608049d, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60805, encodeId=d31360805de, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60807, encodeId=04036080e8e, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893885, encodeId=7f0e18938852a, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 06 08:26:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849508, encodeId=f3cd184950893, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed May 27 22:26:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19551, encodeId=022719551ca, content=预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9daf1619121, createdName=Keren1970, createdTime=Sun Apr 05 20:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572975, encodeId=949415e29759a, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sun Apr 05 11:26:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19485, encodeId=b846194853a, content=外国人工作就是细致, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Sun Apr 05 07:50:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19474, encodeId=6b0f194e442, content=感觉挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Apr 05 01:09:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2016-01-27 doctording1

    是一篇不错的文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=60803, encodeId=b3ec60803a2, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60804, encodeId=3a9b608049d, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60805, encodeId=d31360805de, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60807, encodeId=04036080e8e, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893885, encodeId=7f0e18938852a, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 06 08:26:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849508, encodeId=f3cd184950893, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed May 27 22:26:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19551, encodeId=022719551ca, content=预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9daf1619121, createdName=Keren1970, createdTime=Sun Apr 05 20:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572975, encodeId=949415e29759a, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sun Apr 05 11:26:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19485, encodeId=b846194853a, content=外国人工作就是细致, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Sun Apr 05 07:50:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19474, encodeId=6b0f194e442, content=感觉挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Apr 05 01:09:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2016-01-27 doctording1

    值得进一步关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=60803, encodeId=b3ec60803a2, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60804, encodeId=3a9b608049d, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60805, encodeId=d31360805de, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60807, encodeId=04036080e8e, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893885, encodeId=7f0e18938852a, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 06 08:26:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849508, encodeId=f3cd184950893, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed May 27 22:26:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19551, encodeId=022719551ca, content=预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9daf1619121, createdName=Keren1970, createdTime=Sun Apr 05 20:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572975, encodeId=949415e29759a, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sun Apr 05 11:26:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19485, encodeId=b846194853a, content=外国人工作就是细致, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Sun Apr 05 07:50:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19474, encodeId=6b0f194e442, content=感觉挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Apr 05 01:09:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=60803, encodeId=b3ec60803a2, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60804, encodeId=3a9b608049d, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60805, encodeId=d31360805de, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60807, encodeId=04036080e8e, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893885, encodeId=7f0e18938852a, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 06 08:26:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849508, encodeId=f3cd184950893, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed May 27 22:26:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19551, encodeId=022719551ca, content=预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9daf1619121, createdName=Keren1970, createdTime=Sun Apr 05 20:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572975, encodeId=949415e29759a, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sun Apr 05 11:26:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19485, encodeId=b846194853a, content=外国人工作就是细致, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Sun Apr 05 07:50:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19474, encodeId=6b0f194e442, content=感觉挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Apr 05 01:09:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2015-05-27 windight
  7. [GetPortalCommentsPageByObjectIdResponse(id=60803, encodeId=b3ec60803a2, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60804, encodeId=3a9b608049d, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60805, encodeId=d31360805de, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60807, encodeId=04036080e8e, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893885, encodeId=7f0e18938852a, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 06 08:26:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849508, encodeId=f3cd184950893, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed May 27 22:26:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19551, encodeId=022719551ca, content=预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9daf1619121, createdName=Keren1970, createdTime=Sun Apr 05 20:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572975, encodeId=949415e29759a, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sun Apr 05 11:26:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19485, encodeId=b846194853a, content=外国人工作就是细致, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Sun Apr 05 07:50:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19474, encodeId=6b0f194e442, content=感觉挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Apr 05 01:09:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2015-04-05 Keren1970

    预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=60803, encodeId=b3ec60803a2, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60804, encodeId=3a9b608049d, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60805, encodeId=d31360805de, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60807, encodeId=04036080e8e, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893885, encodeId=7f0e18938852a, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 06 08:26:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849508, encodeId=f3cd184950893, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed May 27 22:26:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19551, encodeId=022719551ca, content=预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9daf1619121, createdName=Keren1970, createdTime=Sun Apr 05 20:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572975, encodeId=949415e29759a, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sun Apr 05 11:26:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19485, encodeId=b846194853a, content=外国人工作就是细致, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Sun Apr 05 07:50:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19474, encodeId=6b0f194e442, content=感觉挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Apr 05 01:09:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=60803, encodeId=b3ec60803a2, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60804, encodeId=3a9b608049d, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60805, encodeId=d31360805de, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60807, encodeId=04036080e8e, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893885, encodeId=7f0e18938852a, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 06 08:26:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849508, encodeId=f3cd184950893, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed May 27 22:26:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19551, encodeId=022719551ca, content=预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9daf1619121, createdName=Keren1970, createdTime=Sun Apr 05 20:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572975, encodeId=949415e29759a, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sun Apr 05 11:26:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19485, encodeId=b846194853a, content=外国人工作就是细致, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Sun Apr 05 07:50:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19474, encodeId=6b0f194e442, content=感觉挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Apr 05 01:09:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2015-04-05 hbwang006

    外国人工作就是细致

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=60803, encodeId=b3ec60803a2, content=不错,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60804, encodeId=3a9b608049d, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60805, encodeId=d31360805de, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60807, encodeId=04036080e8e, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893885, encodeId=7f0e18938852a, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 06 08:26:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849508, encodeId=f3cd184950893, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed May 27 22:26:00 CST 2015, time=2015-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19551, encodeId=022719551ca, content=预实验表明有梗阻性心梗可能性的患者占53.3%。在为期25个月的跟踪随访,出现主要指标,占3.0%左右,说明药物治疗效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9daf1619121, createdName=Keren1970, createdTime=Sun Apr 05 20:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572975, encodeId=949415e29759a, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sun Apr 05 11:26:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19485, encodeId=b846194853a, content=外国人工作就是细致, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Sun Apr 05 07:50:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19474, encodeId=6b0f194e442, content=感觉挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Apr 05 01:09:00 CST 2015, time=2015-04-05, status=1, ipAttribution=)]
    2015-04-05 lecoo

    感觉挺好

    0

相关资讯

CCQO:β受体阻滞剂对冠心病患者没有明显临床疗效

越来越多的证据表明β受体阻滞剂对于患有稳定型冠状动脉心脏病或有其危险因素的患者没有明显临床疗效,这是基于对氯吡格雷加阿司匹林预防动脉粥样硬化事件的对照研究(CHARISMA)的事后分析。 这个分析于2014年9月30日发表在Circulation: Cardiovascular Quality and Outcomes上,使β受体阻滞剂对于冠心病患者明确有益的结论得到进一步否定。 “实际上我们

Diabetes Care:瑞金医院沈卫峰发现ApoA–I糖基化水平与CAD严重程度有关

为了探讨在2型糖尿病患者,脱辅基蛋白(apo)A–I糖基化水平是否与冠状动脉疾病(CAD)和斑块进展有关,来自上海交通大学附属瑞金医院心内科的沈卫峰教授及其团队进行了一项研究(Glycation of apoprotein a-I is associated with coronary artery plaque progression in type 2 diabetic patients),该

介入与否——稳定性冠心病的两难抉择

导语:COURAGE研究结果发表之时曾引起学界的广泛热议,最新发表的荟萃分析与2007年COURAGE研究结果遥相呼应,其结果表明,稳定性冠状动脉疾病(CAD)患者在理想药物治疗基础上增加经皮冠状动脉介入治疗(PCI)只能轻度缓解疼痛,对死亡与心肌梗死并无保护作用。荟萃分析的作者、美国纽约大学Bangalore博士进一步指出,该荟萃分析中纳入的临床试验较既往更为严格,结果更为可靠,如,排除了入

medscape:CAD患者,性别差异造成影响不同

新的研究结果表明,由于男性和女性的生理心理不同,患者对于稳定性心绞痛(CAD)产生的精神压力不同。这个结论一旦被确认,将解释为什么患CAD的女性的状况比男性差,这将为风险评估和治疗提供新观点。 在经过3项压力测试后,患有CAD的男性相对于女性,在血压和其他传统危险因素方面更有可能发生变化。但患有CAD的女性心脏血流灌注减少(精神压力造成的心肌缺血);女性也更易产生胶原刺激引起的血小板聚集;同时,

JACC:3D心肌灌注磁共振显像预测CAD更佳

    2012年7月18日《美国心脏病学会杂志》(JACC)发表论文称,3D心肌灌注磁共振显像(MRI)可准确预测血流储备分数(FFR)测定的致缺血狭窄,冠心病患者无创诊断和危险分层具有可行性。伦敦国王学院的Sven Plein研究组检查了53例患者(平均63岁)3D心肌灌注MRI对比血管造影期间测量的FFR诊断血流受限冠脉狭窄的准确性。研究人群总发病率6

NEJM:可疑冠状动脉疾病的非侵入性检查比较(PROMISE试验)

Exception Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/>